US-based biopharmaceutical company Alnylam Pharmaceuticals has begun a Phase I/II clinical trial of ALN-HBV to treat patients with chronic hepatitis B virus (HBV) infection.

ALN-HBV is an investigational RNAi therapeutic administered subcutaneously.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The randomised, single-blind, placebo-controlled Phase I/II trial of ALN-HBV is being conducted in three sequential parts.

Part A is a single-dose study designed to involve up to 24 normal healthy volunteers (NHVs).

"High unmet need remains for safe and effective HBV therapies with the potential to produce functional cures after a finite treatment period."

Part B is a single-dose study planning to include up to a total of 28 patients with chronic HBV infection, while Part C will be a multi-dose study designed to enrol up to 48 patients with chronic HBV infection.

See Also:

The trial is primarily focused on evaluating the safety and tolerability of ALN-HBV when administered subcutaneously in single and multiple subcutaneous doses.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The secondary objectives of the trial will entail assessment of pharmacokinetics profile and clinical antiviral activity for ALN-HBV, as measured by its effects on serum HBsAg levels in hepatitis B envelope antigen (HBeAg) positive and negative chronic HBV patients.

Alnylam hepatic infectious disease strategic therapeutic area (STAr) programme leader entrepreneur-in-residence vice-president Laura Sepp-Lorenzino said: "We believe ALN-HBV has the potential to become a best-in-class, once-monthly, subcutaneous treatment regimen for the treatment of chronic HBV infection, including patients with both HBeAg-positive and HBeAg-negative disease.

"We are encouraged by the pre-clinical results with ALN-HBV demonstrating potent and durable knockdown of plasma HBV surface antigen (HBsAg) in rodent models of HBV infection.

"High unmet need remains for safe and effective HBV therapies with the potential to produce functional cures after a finite treatment period."

ALN-HBV operates on the company's enhanced stabilisation chemistry (ESC)-GalNAc-siRNA conjugate delivery platform, which facilitates potency and durability with a very wide therapeutic index.

Previous studies conducted on rodent HBV models have displayed that the subcutaneous administration of ALN-HBV is effective with lasting duration and has also demonstrated tolerability after administration.